174 related articles for article (PubMed ID: 16269007)
1. Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of Parkinson's disease.
van den Munckhof P; Gilbert F; Chamberland M; Lévesque D; Drouin J
J Neurochem; 2006 Jan; 96(1):160-70. PubMed ID: 16269007
[TBL] [Abstract][Full Text] [Related]
2. Molecular and cellular alterations in the Pitx3-deficient midbrain dopaminergic system.
Smits SM; Mathon DS; Burbach JP; Ramakers GM; Smidt MP
Mol Cell Neurosci; 2005 Nov; 30(3):352-63. PubMed ID: 16140547
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic segregation of aphakia and Pitx3-null mutants reveals that Pitx3 deficiency increases consolidation of specific movement components.
Kas MJ; van der Linden AJ; Oppelaar H; von Oerthel L; Ramakers GM; Smidt MP
Behav Brain Res; 2008 Jan; 186(2):208-14. PubMed ID: 17919745
[TBL] [Abstract][Full Text] [Related]
4. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
[TBL] [Abstract][Full Text] [Related]
5. Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3.
Smidt MP; Smits SM; Bouwmeester H; Hamers FP; van der Linden AJ; Hellemons AJ; Graw J; Burbach JP
Development; 2004 Mar; 131(5):1145-55. PubMed ID: 14973278
[TBL] [Abstract][Full Text] [Related]
6. In-vitro analysis of Pitx3 in mesodiencephalic dopaminergic neuron maturation.
Papanikolaou T; Amano T; Lennington J; Sink K; Farrar AM; Salamone J; Yang X; Conover JC
Eur J Neurosci; 2009 Jun; 29(12):2264-75. PubMed ID: 19508691
[TBL] [Abstract][Full Text] [Related]
7. The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.
Ekstrand MI; Galter D
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S185-8. PubMed ID: 20082987
[TBL] [Abstract][Full Text] [Related]
8. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
9. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
10. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons.
van den Munckhof P; Luk KC; Ste-Marie L; Montgomery J; Blanchet PJ; Sadikot AF; Drouin J
Development; 2003 Jun; 130(11):2535-42. PubMed ID: 12702666
[TBL] [Abstract][Full Text] [Related]
11. Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3
Suarez LM; Alberquilla S; García-Montes JR; Moratalla R
J Neurosci; 2018 Apr; 38(15):3619-3630. PubMed ID: 29483281
[TBL] [Abstract][Full Text] [Related]
12. Homeobox gene Pitx3 and its role in the development of dopamine neurons of the substantia nigra.
Smidt MP; Smits SM; Burbach JP
Cell Tissue Res; 2004 Oct; 318(1):35-43. PubMed ID: 15300495
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
14. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
[TBL] [Abstract][Full Text] [Related]
15. A Pitx3-deficient developmental mouse model for fine motor, olfactory, and gastrointestinal symptoms of Parkinson's disease.
Song B; Feldmann JW; Cao S; Feitosa M; Kong Y; Kim W; Schweitzer A; Leblanc P; Schweitzer JS; Kim KS
Neurobiol Dis; 2022 Aug; 170():105777. PubMed ID: 35636646
[TBL] [Abstract][Full Text] [Related]
16. The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress.
Luk KC; Rymar VV; van den Munckhof P; Nicolau S; Steriade C; Bifsha P; Drouin J; Sadikot AF
J Neurochem; 2013 Jun; 125(6):932-43. PubMed ID: 23331067
[TBL] [Abstract][Full Text] [Related]
17. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
Mercuri NB; Bernardi G
Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
[TBL] [Abstract][Full Text] [Related]
18. 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease.
Hwang DY; Fleming SM; Ardayfio P; Moran-Gates T; Kim H; Tarazi FI; Chesselet MF; Kim KS
J Neurosci; 2005 Feb; 25(8):2132-7. PubMed ID: 15728853
[TBL] [Abstract][Full Text] [Related]
19. What has been learnt from study of dopamine receptors in Parkinson's disease?
Hurley MJ; Jenner P
Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
[TBL] [Abstract][Full Text] [Related]
20. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice.
Hwang DY; Ardayfio P; Kang UJ; Semina EV; Kim KS
Brain Res Mol Brain Res; 2003 Jun; 114(2):123-31. PubMed ID: 12829322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
